Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults
NCT ID: NCT05847673
Last Updated: 2024-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
125 participants
INTERVENTIONAL
2023-08-20
2024-06-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers
NCT04194918
Tobacco Cessation for Sexual Minorities
NCT03643679
SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups
NCT05645354
A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle
NCT05304390
Identify the Usefulness of Peer-facilitated Versus Self-navigated Quit Tobacco Program for Youths.
NCT06053762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM I: Participants receive self-guided, online quit smoking program, called EQQUAL Program A.
ARM II: Participants receive self-guided online quit smoking program, EQQUAL Program B.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (EQQUAL A)
Participants receive self-guided online EQQUAL A program on study. Participants also receive motivational messages and smoking cessation information via text messages.
Online Smoking Cessation Intervention
Receive EQQUAL A intervention
Questionnaire Administration
Ancillary studies
Health Promotion and Education
Receive motivational messages and smoking cessation information via SMS text messages
Arm II (EQQUAL B)
Participants receive self-guided online EQQUAL B program on study. Participants also receive motivational messages and smoking cessation information via text messages.
Online Smoking Cessation Intervention
Receive EQQUAL B intervention
Questionnaire Administration
Ancillary studies
Health Promotion and Education
Receive motivational messages and smoking cessation information via SMS text messages
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Online Smoking Cessation Intervention
Receive EQQUAL A intervention
Online Smoking Cessation Intervention
Receive EQQUAL B intervention
Questionnaire Administration
Ancillary studies
Health Promotion and Education
Receive motivational messages and smoking cessation information via SMS text messages
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must self-identify being between 18 and 30 years of age
* Participants must self-identify as a sexual and/or gender minority (i.e., a sexual orientation other than straight and/or gender that doesn't match sex assigned at birth)
* Participants must currently reside in the United States, with a United States (US) mailing address, and anticipate remaining in the US for the duration of the study (3 months)
* SMOKING CRITERIA:
* Participants must self-report smoking at least 1 cigarette per day in the 30 days prior to screening
* TREATMENT ACCESSIBILITY:
* Participants must self-report having at least weekly Internet access for the next three months
* Participants must self-report being willing and able to stream audio and video online for this study
* Participants must self-report current use of a personal email account
* Participants must self-report current use of text messaging
* OTHER CRITERIA:
* Participants must self-report that they are interested in participating in the study for themselves (versus \[vs\] someone else)
* Participants must self-report that they have not participated in one of our prior smoking cessation studies
* Participants must self-report that they are comfortable reading, writing, and speaking English
* Participants must self-report that they understand and agree to the conditions of compensation
* Participants must self-report that they are not currently incarcerated
* Participants must be willing to use the assigned intervention program, complete the study assessments, and consent to participate in this study
* Participants must be willing to upload a photo of themselves (face visible)
Exclusion Criteria
* Participants must not be a member of the same household as another research participant
* Having a Google voice number as their sole phone number
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Leonard and Norma Klorfine Foundation
UNKNOWN
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaimee Heffner
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2023-03050
Identifier Type: REGISTRY
Identifier Source: secondary_id
RG1123270
Identifier Type: OTHER
Identifier Source: secondary_id
RG1123270
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.